Ziprasidone intramuscular/oral in the treatment of acute exacerbation of schizophrenia or schizoaffective disorder: A six-week open administration study

Trial Profile

Ziprasidone intramuscular/oral in the treatment of acute exacerbation of schizophrenia or schizoaffective disorder: A six-week open administration study

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Apr 2008

At a glance

  • Drugs Ziprasidone; Ziprasidone
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top